Leustat Subcutaneous (Cladribine)

Cladribine is a purine nucleoside analog that is converted inside cells to an active triphosphate form. This metabolite incorporates into DNA, causing strand breaks and inhibiting DNA synthesis, which selectively depletes lymphocytes, especially the malignant B‑cells responsible for hairy cell leukemia.

The dosing regimen for Leustat Subcutaneous is determined by the prescribing physician based on the patient’s clinical condition, disease stage, and laboratory parameters. Healthcare professionals tailor the dose to achieve optimal therapeutic effect while minimizing toxicity.

Cladribine may pose risks to a developing fetus and is generally not recommended during pregnancy unless the potential benefit justifies the risk. Breastfeeding is also discouraged while on therapy because the drug can be excreted in milk. Consultation with a specialist is essential.

To request Leustat Subcutaneous, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Leustat Subcutaneous (cladribine) is an antimetabolite that offers a convenient subcutaneous route and a well‑characterized efficacy profile. Compared with purine analogs like pentostatin, cladribine often requires fewer treatment cycles and has a distinct safety spectrum, though both share risks of immunosuppression.

Leustat Subcutaneous should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Leustat Subcutaneous is given by subcutaneous injection, typically performed by a healthcare professional in a clinical setting. The injection site is rotated to minimize local irritation, and patients are observed for any immediate adverse reactions.

The most serious risks include severe infections due to profound lymphopenia, secondary malignancies, and significant cytopenias such as anemia, thrombocytopenia, and neutropenia. Prompt monitoring of blood counts and infection signs is essential throughout therapy.

Leustat Subcutaneous is contraindicated in patients with active uncontrolled infections, those receiving live vaccines, and individuals with known hypersensitivity to cladribine or any excipients. Caution is also advised for patients with severe hepatic or renal impairment.